Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $3.2 million.

  • Spyre Therapeutics' Other Non-Current Liabilities fell 9106.75% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 9106.75%. This contributed to the annual value of $36.6 million for FY2024, which is 1135.32% down from last year.
  • Spyre Therapeutics' Other Non-Current Liabilities amounted to $3.2 million in Q3 2025, which was down 9106.75% from $16.5 million recorded in Q1 2025.
  • In the past 5 years, Spyre Therapeutics' Other Non-Current Liabilities registered a high of $194.2 million during Q2 2023, and its lowest value of $8000.0 during Q1 2022.
  • For the 5-year period, Spyre Therapeutics' Other Non-Current Liabilities averaged around $30.6 million, with its median value being $18.6 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Other Non-Current Liabilities soared by 79565.22% in 2021, and later tumbled by 9611.65% in 2022.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Other Non-Current Liabilities stood at $16000.0 in 2021, then tumbled by 50.0% to $8000.0 in 2022, then skyrocketed by 516275.0% to $41.3 million in 2023, then decreased by 11.35% to $36.6 million in 2024, then tumbled by 91.18% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $16.5 million for Q1 2025, and $36.6 million during Q4 2024.